Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT Days Sales Outstanding is 37.05 as of Jun. 2026, which is 17% above its 10-year median of 31.76. The stock has 7 warning signs investors should review. Among 946 Drug Manufacturers companies, Vitura Health ranks better than 88.9% on this metric.
Vitura Health's average Accounts Receivable for the
six
months ended in Jun. 2026 was A$12.8 Mil. Vitura Health's Revenue for the
six
months ended in Jun. 2026 was A$63.3 Mil.
Hence, Vitura Health's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 37.05.
The historical rank and industry rank for Vitura Health's Days Sales Outstanding or its related term are showing as below:
ASX:VIT'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.51 Med: 31.76 Max: 69.17
Current: 33.12
During the past 8 years, Vitura Health's highest Days Sales Outstanding was 69.17. The lowest was 16.51. And the median was 31.76.
ASX:VIT's Days Sales Outstanding is ranked better than 88.9% of 946
companies
in the Drug Manufacturers industry
Industry Median: 71.925
vs ASX:VIT: 33.12
Vitura Health's Days Sales Outstanding
increased
from Jun. 2025 (28.02) to Jun. 2026 (37.05).
Vitura Health (ASX:VIT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Vitura Health Days Sales Outstanding Related Terms
Vitura Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Vitura Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Vitura Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a Days Sales Outstanding of 37.05 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vitura Health and its competitors. This is 17% above median its historical median of 31.76. Over the past decade, Vitura Health's Days Sales Outstanding has ranged from 16.51 to 69.17. According to the industry distribution chart, Vitura Health ranks #105 out of 946 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Vitura Health's Days Sales Outstanding too high?
Vitura Health's current Days Sales Outstanding of 37.05 is 17% above median its 10-year median of 31.76. Over the past 10 years, this metric has ranged from a low of 16.51 to a high of 69.17. The Drug Manufacturers industry median Days Sales Outstanding is 71.93. Vitura Health's value of 37.05 is 48.5% below this industry median. Based on the distribution chart, Vitura Health ranks #105 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Vitura Health's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #105 out of 946 companies for Days Sales Outstanding. This places Vitura Health in the top 11% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.93. Vitura Health's value of 37.05 is 48.5% below this benchmark. Historically, Vitura Health's own Days Sales Outstanding has ranged from 16.51 to 69.17 over the past decade. While the company's 10-year median is 31.76 vs. the industry median of 71.93, Vitura Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.93, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current Days Sales Outstanding of 37.05 is 48.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Days Sales Outstanding is 37.05, which is 17% above median its own 10-year median of 31.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.07, compared to a current price of A$0.02 — trading 70% below its estimated fair value. The current Days Sales Outstanding is 37.05, which is 17% above median its 10-year median of 31.76 and 48.5% below the Drug Manufacturers industry median of 71.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Days Sales Outstanding is 37.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
